KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over its moving
averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade
in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic
reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and
$75.00 for most of the position in consideration of the analyst report.
